Amylyx Pharmaceuticals, Inc. (AMLX) announced that it will remove its amyotrophic lateral sclerosis (ALS) drug Relyvrio (sodium phenylbutyrate and taurursodiol, also known as AMX0035) from the U.S. markets and it has already started a process with the FDA on the same.The drug, approved under the brand name Albrioza in Canada, will also be removed from Canadian markets.While the formal decision to remove the drug from these markets has come recently, the company was contemplating the same following the failu ...